Business
Scholar Rock to Present New Preclinical Data on its Targeted Approach to the LTBP-TGFβ1 Complex for Anti-Fibrotic Therapy at the 2022 FASEB Science Research Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious
About this update from Scholar Rock Holding Corporation
[{"type":"text","content":" CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nScholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the company will present new data that highlight the development of its highly selective, context-dependent TGFβ1 antibody that inhibits proTGFβ1 activation selectively in the context of its extracellular matrix presenting partner, latent TGFβ binding protein (“LTBP”; the target is collectively identified as “LTBP-TGFβ1”). The data show reduction of TGFβ1 signaling and reduction of fibrosis in relevant preclinical models in vivo. These findings will be presented in an oral and poster presentation at the 2022 FASEB Science Research Conference (SRC), taking place between July 17–21, 2022 in Malahide, Ireland.\n\n“TGFβ1 plays a complex role in human disease, including fibrosis progression and immune regulation. Our earlier work established the isoform-selective approach to TGFb1 inhibition,” said Gregory Carven, Ph.D., Chief Scientific Officer of Scholar Rock. “This new research extends this idea further, showing that highly selective antibodies that inhibit TGFβ1 associated with specific extracellular matrix proteins can distinguish between the profibrotic and immunomodulatory activities of TGFβ1, and could potentially provide a safe and effective way to treat a wide range of fibrotic diseases—such as Alport syndrome, scleroderma or idiopathic pulmonary fibrosis—with a lower potential for immune-mediated side-effects.”\n\nData being featured at FASEB SRC will be made available in the Publications & Posters section of Scholar Rock’s website after the presentation:\n\nOral Presentation: Selective Targeting of Matrix-Associated TGFBeta1 as an Attractive Approach for Anti-Fibrotic Therapy\nPresenter: Rohan Manohar, Ph.D., Associate Director of Discovery Biology at Scholar Rock\nSession: TGF-β Superfamily: Signaling in Development and Disease\nTime: July 21, 9:45 a.m. CET\n\nFor conference information visit https://www.faseb.org/meetings-and-events/src-events/the-tgf-%CE%B2-superfamily-conference-signaling-in-development-and-disease.\n\nAbout Scholar Rock\nScholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of seri...